FLGT Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
90.4M
+5.9%
85.4M
+20.0%
71.1M
-14.6%
83.3M
-0.9%
84.1M
Cost of Revenue
58.5M
-2.1%
59.7M
+20.3%
49.6M
-2.2%
50.8M
+4.5%
48.6M
Gross Profit
31.9M
+24.4%
25.7M
+19.5%
21.5M
-34.0%
32.6M
-8.3%
35.5M
Operating Expenses
54.5M
-11.8%
61.8M
+10.1%
56.1M
-18.5%
68.8M
+35.3%
50.9M
R&D
13.6M
-6.3%
14.6M
+2.7%
14.2M
+0.0%
14.2M
+2.2%
13.9M
SG&A
38.4M
-9.6%
42.4M
+6.3%
39.9M
-24.2%
52.6M
+50.5%
35.0M
Operating Income
-22547000
+37.5%
-36073000
-4.2%
-34622000
+4.5%
-36238000
-136.1%
-15350000
EBITDA
-15731000
+40.0%
-26225000
+8.4%
-28622000
+5.0%
-30126000
-223.5%
-9312000
Net Income
-13339000
+55.1%
-29719000
-17.6%
-25274000
-6.9%
-23650000
-246.5%
-6826000
EPS (Basic)
$-0.48
+54.3%
$-1.05
-31.3%
$-0.80
-5.3%
$-0.76
-261.9%
$-0.21
EPS (Diluted)
$-0.48
+54.3%
$-1.05
-31.3%
$-0.80
-5.3%
$-0.76
-261.9%
$-0.21
Shares (Diluted)
27.7M
-1.2%
28.0M
-9.3%
30.9M
-0.3%
31.0M
+0.8%
30.7M
Fulgent Genetics (FLGT) — Financials